ATE414556T1 - Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten - Google Patents

Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten

Info

Publication number
ATE414556T1
ATE414556T1 AT03714958T AT03714958T ATE414556T1 AT E414556 T1 ATE414556 T1 AT E414556T1 AT 03714958 T AT03714958 T AT 03714958T AT 03714958 T AT03714958 T AT 03714958T AT E414556 T1 ATE414556 T1 AT E414556T1
Authority
AT
Austria
Prior art keywords
inhibitors
treat
vascular disease
peripheral vascular
prevent peripheral
Prior art date
Application number
AT03714958T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of ATE414556T1 publication Critical patent/ATE414556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03714958T 2002-03-22 2003-03-13 Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten ATE414556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22

Publications (1)

Publication Number Publication Date
ATE414556T1 true ATE414556T1 (de) 2008-12-15

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03714958T ATE414556T1 (de) 2002-03-22 2003-03-13 Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten

Country Status (27)

Country Link
US (2) US9592267B2 (de)
EP (1) EP1487541B1 (de)
JP (1) JP4885424B2 (de)
KR (1) KR20050004809A (de)
CN (1) CN100540058C (de)
AR (1) AR039103A1 (de)
AT (1) ATE414556T1 (de)
AU (1) AU2003219162B2 (de)
BR (1) BRPI0308663B8 (de)
CA (1) CA2478855C (de)
CY (1) CY1108748T1 (de)
DE (1) DE60324777D1 (de)
DK (1) DK1487541T3 (de)
EA (1) EA008495B1 (de)
ES (1) ES2314191T3 (de)
HR (1) HRP20040758B1 (de)
IL (2) IL164211A0 (de)
ME (1) ME00548B (de)
MX (1) MXPA04009135A (de)
NO (1) NO336226B1 (de)
PL (1) PL207303B1 (de)
PT (1) PT1487541E (de)
RS (1) RS51755B (de)
SI (1) SI1487541T1 (de)
UA (1) UA80275C2 (de)
WO (1) WO2003080104A2 (de)
ZA (1) ZA200407022B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
AU2006256763B2 (en) 2005-06-10 2012-08-02 Ares Trading S.A. Process for the purification of IL-18 binding protein
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (de) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1-Rezeptorantagonisten-reiche Lösungen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
RU2505291C2 (ru) 2009-06-24 2014-01-27 СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи Топическая композиция, содержащая ибупрофен
WO2011031553A2 (en) 2009-08-27 2011-03-17 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
AR082518A1 (es) 2010-08-25 2012-12-12 Hoffmann La Roche Anticuerpos contra il-18r1 y usos de los mismos
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) * 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
EP3074507B1 (de) 2013-11-26 2022-01-05 Biomet Biologics, LLC Verfahren zur vermittlung von makrophagenphänotypen
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
UA128752C2 (uk) 2015-03-05 2024-10-16 Аб2 Біо Са Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
CA2324168A1 (en) * 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
CZ300792B6 (cs) * 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja

Also Published As

Publication number Publication date
ME00548B (me) 2011-10-10
HRP20040758B1 (hr) 2012-10-31
PL372398A1 (en) 2005-07-25
US9566313B2 (en) 2017-02-14
BRPI0308663B8 (pt) 2021-05-25
EA200401240A1 (ru) 2005-02-24
AU2003219162A1 (en) 2003-10-08
WO2003080104A3 (en) 2004-03-04
PT1487541E (pt) 2008-12-10
IL164211A0 (en) 2005-12-18
US9592267B2 (en) 2017-03-14
CN100540058C (zh) 2009-09-16
US20060233799A1 (en) 2006-10-19
CY1108748T1 (el) 2014-04-09
DK1487541T3 (da) 2009-01-19
JP2005520852A (ja) 2005-07-14
EP1487541B1 (de) 2008-11-19
DE60324777D1 (de) 2009-01-02
CA2478855C (en) 2013-12-17
CA2478855A1 (en) 2003-10-02
NO336226B1 (no) 2015-06-22
IL164211A (en) 2011-07-31
US20100291028A1 (en) 2010-11-18
MXPA04009135A (es) 2004-12-07
PL207303B1 (pl) 2010-11-30
JP4885424B2 (ja) 2012-02-29
CN1655845A (zh) 2005-08-17
EA008495B1 (ru) 2007-06-29
SI1487541T1 (sl) 2009-02-28
UA80275C2 (en) 2007-09-10
KR20050004809A (ko) 2005-01-12
RS51755B (sr) 2011-12-31
AR039103A1 (es) 2005-02-09
ZA200407022B (en) 2006-06-28
BR0308663A (pt) 2005-01-25
ES2314191T3 (es) 2009-03-16
EP1487541A2 (de) 2004-12-22
HRP20040758A2 (en) 2005-02-28
HK1075422A1 (zh) 2005-12-16
NO20044459L (no) 2004-10-20
WO2003080104A2 (en) 2003-10-02
AU2003219162B2 (en) 2008-01-03
BRPI0308663B1 (pt) 2019-07-16
RS81504A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE499105T1 (de) Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
EP1191941A4 (de) Methode der prophylaxe und/oder behandlung von erkrankungen
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE417616T1 (de) Behandlung von mukositis
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
EP1592464A4 (de) Verfahren zur behandlung von kognitivem verfall aufgrund von schlafmangel und stress
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
ATE410169T1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
EP1817039A4 (de) Behandlung und prävention von epilepsie
ATE257384T1 (de) Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487541

Country of ref document: EP

EEFA Change of the company name